Sinovation Medical

Sinovation Medical Technology Co., Ltd., established in August 2015, is a medical technology firm focused on developing and manufacturing intelligent medical devices for neurosurgery. The company provides comprehensive technology and product solutions for treating brain diseases like epilepsy, Parkinson's disease, brain tumors, and cerebral hemorrhage. Its technology originates from two decades of research at Tsinghua University.

The company was co-founded by Wang Ke, Wu Di, and Dr. Liu Wenbo. Wang Ke, a graduate of Peking University's Health Science Center, has extensive clinical and business experience. Wu Di, an alumnus of Xi'an Jiaotong University Health Science Center, previously worked at Capital Medical University Xuanwu Hospital. Dr. Liu Wenbo holds a Ph.D. from Tsinghua University's School of Medicine and has deep expertise in neurosurgical navigation systems. Their journey began in 2005 when Wu Di and Wang Ke founded Beijing Huake Hengsheng Medical Technology to develop and produce medical electrodes for neurosurgery. Recognizing the limitations in the market, they decided to develop surgical robots, initiating research and development with Tsinghua University in 2011, which led to the formation of Sinovation Medical.

Sinovation Medical operates on a business model that combines the sale of high-end medical equipment with associated high-value consumables and technical services. Its clients are primarily hospitals and medical institutions, with its products used in over 250 hospitals across China. The firm has established a significant market presence, with its intracranial electrodes and neurosurgical robots holding a leading share in the domestic market. The business has expanded globally, notably after receiving FDA approval for its Sinobot X1, paving the way for international sales.

The company's product portfolio is organized into six main lines: the SR series of neurosurgical robots, the Q300 series of miniature neurosurgical robots, the NS series of neurosurgical navigation systems, the X1000 series for brain and spinal surgery, the LS series of MRI-guided laser ablation therapy systems, and a comprehensive range of intracranial electrodes through its subsidiary, Huake Hengsheng. A key product, the Sinobot X1, is the first neurosurgical robot from a Chinese company to receive FDA clearance in the United States. Another significant offering is the Laser Interstitial Thermal Therapy (LITT) system, the first domestically developed system of its kind in China for treating brain tumors and epilepsy. The company's robots integrate advanced features like 3D structured light for markerless registration, enhancing surgical precision and efficiency.

Keywords: neurosurgical robotics, medical devices, stereotactic surgery, minimally invasive neurosurgery, surgical navigation systems, intracranial electrodes, laser ablation therapy, epilepsy treatment, brain tumor treatment, Parkinson's disease treatment, medical imaging software, Sinobot, Huake Hengsheng, medtech, healthcare technology, surgical planning, robotic-assisted surgery, Class III medical devices, NMPA approved, FDA cleared